P-21
Dyslipidemia / Hypercholesterolemia
PreclinicalActive
Key Facts
About Shifa Biomedical
Shifa Biomedical is a U.S.-based drug discovery company targeting cardiovascular disease with a focus on dyslipidemia. Its primary asset is P-21, a preclinical, orally bioavailable small molecule designed to inhibit PCSK9 and lower LDL cholesterol, positioning it as a potential first-in-class oral alternative to injectable monoclonal antibodies. The company is privately held, pre-revenue, and utilizes a hybrid discovery platform combining experimental and virtual screening. While the science is promising, Shifa faces significant risks typical of early-stage biotechs, including clinical development hurdles and intense competition in the lipid-lowering market.
View full company profile